Chair
Member
Chairman of the board
Financial expert
Audit Committee Position

Jay M. Moyes  

Mr. Moyes currently serves as Chief Financial Officer of Sera Prognostics, Inc., a public commercial stage biotechnology company focused on improving maternal and neonatal health through innovative biomarker approaches, and currently serves on the board of directors of BioCardia, Inc., and Puma Biotechnology, Inc. He previously served on the boards of Predictive Technology Group, Osiris Therapeutics, Inc., Integrated Diagnostics and as Chief Financial Officer and Director of Amedica Corporation (now SINTX Technologies). Mr. Moyes also served as Chief Financial Officer of CareDx, a publicly traded cardiovascular diagnostics company. Prior to that, he served as Chief Financial Officer of Myriad Genetics, Inc., a publicly held molecular diagnostics company. Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc. from 1991 until 1993, a privately held animal genetics company. Mr. Moyes held various positions with the accounting firm of KPMG from 1979 to 1991. He also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 to 2006. Mr. Moyes holds a Masters of Business Administration from the University of Utah, a Bachelor of Arts in economics from Weber State University, and was formerly a Certified Public Accountant.

Chair

Donald R. Joseph

Mr. Joseph currently serves as Chief Legal Officer and Board Secretary of Acer Therapeutics Inc., a publicly held biopharmaceutical company, and has served as an adviser and consultant to biopharmaceutical and global health organizations. He has over twenty years of biopharmaceutical industry experience, including senior management positions in global health non-profit organizations. Mr. Joseph served as the Chief Legal Officer and Board Secretary of Humanigen, formerly known as KaloBios Pharmaceuticals, Inc., a publicly listed company, from June 2013 to November 2015. Prior to KaloBios, he was Chief Executive Officer of BIO Ventures for Global Health, or BVGH, from February to November 2012 and Chief Operating Officer from April 2010 to January 2012. He is a former Chairman and Secretary and director of BVGH. He previously served as general counsel, corporate secretary, and in other senior management roles at publicly held biopharmaceutical companies, including Abgenix and Renovis. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world’s largest law firms. He received his J.D. degree from the University of Texas School of Law, with honors.

Member

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Member

Martin Mattingly, Pharm.D.

Dr. Mattingly served as a director of Achieve since June 2010. Since December 2014 he has served as a director of TRACON Pharmaceuticals, Inc. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007, Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005, Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky.

Member

Audit Committee Charter

Download
Compensation Committee Position

Martin Mattingly, Pharm.D.

Dr. Mattingly served as a director of Achieve since June 2010. Since December 2014 he has served as a director of TRACON Pharmaceuticals, Inc. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007, Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005, Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky.

Chair

Donald R. Joseph

Mr. Joseph currently serves as Chief Legal Officer and Board Secretary of Acer Therapeutics Inc., a publicly held biopharmaceutical company, and has served as an adviser and consultant to biopharmaceutical and global health organizations. He has over twenty years of biopharmaceutical industry experience, including senior management positions in global health non-profit organizations. Mr. Joseph served as the Chief Legal Officer and Board Secretary of Humanigen, formerly known as KaloBios Pharmaceuticals, Inc., a publicly listed company, from June 2013 to November 2015. Prior to KaloBios, he was Chief Executive Officer of BIO Ventures for Global Health, or BVGH, from February to November 2012 and Chief Operating Officer from April 2010 to January 2012. He is a former Chairman and Secretary and director of BVGH. He previously served as general counsel, corporate secretary, and in other senior management roles at publicly held biopharmaceutical companies, including Abgenix and Renovis. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world’s largest law firms. He received his J.D. degree from the University of Texas School of Law, with honors.

Member

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Member

Compensation Committee Charter

Download
Nominating and Corporate Governance Committee Position

Donald R. Joseph

Mr. Joseph currently serves as Chief Legal Officer and Board Secretary of Acer Therapeutics Inc., a publicly held biopharmaceutical company, and has served as an adviser and consultant to biopharmaceutical and global health organizations. He has over twenty years of biopharmaceutical industry experience, including senior management positions in global health non-profit organizations. Mr. Joseph served as the Chief Legal Officer and Board Secretary of Humanigen, formerly known as KaloBios Pharmaceuticals, Inc., a publicly listed company, from June 2013 to November 2015. Prior to KaloBios, he was Chief Executive Officer of BIO Ventures for Global Health, or BVGH, from February to November 2012 and Chief Operating Officer from April 2010 to January 2012. He is a former Chairman and Secretary and director of BVGH. He previously served as general counsel, corporate secretary, and in other senior management roles at publicly held biopharmaceutical companies, including Abgenix and Renovis. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world’s largest law firms. He received his J.D. degree from the University of Texas School of Law, with honors.

Chair

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Member

Martin Mattingly, Pharm.D.

Dr. Mattingly served as a director of Achieve since June 2010. Since December 2014 he has served as a director of TRACON Pharmaceuticals, Inc. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007, Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005, Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky.

Member

Jay M. Moyes  

Mr. Moyes currently serves as Chief Financial Officer of Sera Prognostics, Inc., a public commercial stage biotechnology company focused on improving maternal and neonatal health through innovative biomarker approaches, and currently serves on the board of directors of BioCardia, Inc., and Puma Biotechnology, Inc. He previously served on the boards of Predictive Technology Group, Osiris Therapeutics, Inc., Integrated Diagnostics and as Chief Financial Officer and Director of Amedica Corporation (now SINTX Technologies). Mr. Moyes also served as Chief Financial Officer of CareDx, a publicly traded cardiovascular diagnostics company. Prior to that, he served as Chief Financial Officer of Myriad Genetics, Inc., a publicly held molecular diagnostics company. Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc. from 1991 until 1993, a privately held animal genetics company. Mr. Moyes held various positions with the accounting firm of KPMG from 1979 to 1991. He also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 to 2006. Mr. Moyes holds a Masters of Business Administration from the University of Utah, a Bachelor of Arts in economics from Weber State University, and was formerly a Certified Public Accountant.

Member

Nominating and Corporate Governance Committee Charter

Download

Jay M. Moyes

Mr. Moyes currently serves as Chief Financial Officer of Sera Prognostics, Inc., a public commercial stage biotechnology company focused on improving maternal and neonatal health through innovative biomarker approaches, and currently serves on the board of directors of BioCardia, Inc., and Puma Biotechnology, Inc. He previously served on the boards of Predictive Technology Group, Osiris Therapeutics, Inc., Integrated Diagnostics and as Chief Financial Officer and Director of Amedica Corporation (now SINTX Technologies). Mr. Moyes also served as Chief Financial Officer of CareDx, a publicly traded cardiovascular diagnostics company. Prior to that, he served as Chief Financial Officer of Myriad Genetics, Inc., a publicly held molecular diagnostics company. Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc. from 1991 until 1993, a privately held animal genetics company. Mr. Moyes held various positions with the accounting firm of KPMG from 1979 to 1991. He also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 to 2006. Mr. Moyes holds a Masters of Business Administration from the University of Utah, a Bachelor of Arts in economics from Weber State University, and was formerly a Certified Public Accountant.

Donald R. Joseph

Mr. Joseph currently serves as Chief Legal Officer and Board Secretary of Acer Therapeutics Inc., a publicly held biopharmaceutical company, and has served as an adviser and consultant to biopharmaceutical and global health organizations. He has over twenty years of biopharmaceutical industry experience, including senior management positions in global health non-profit organizations. Mr. Joseph served as the Chief Legal Officer and Board Secretary of Humanigen, formerly known as KaloBios Pharmaceuticals, Inc., a publicly listed company, from June 2013 to November 2015. Prior to KaloBios, he was Chief Executive Officer of BIO Ventures for Global Health, or BVGH, from February to November 2012 and Chief Operating Officer from April 2010 to January 2012. He is a former Chairman and Secretary and director of BVGH. He previously served as general counsel, corporate secretary, and in other senior management roles at publicly held biopharmaceutical companies, including Abgenix and Renovis. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world’s largest law firms. He received his J.D. degree from the University of Texas School of Law, with honors.

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Martin Mattingly, Pharm.D.

Dr. Mattingly served as a director of Achieve since June 2010. Since December 2014 he has served as a director of TRACON Pharmaceuticals, Inc. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007, Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005, Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky.

Martin Mattingly, Pharm.D.

Dr. Mattingly served as a director of Achieve since June 2010. Since December 2014 he has served as a director of TRACON Pharmaceuticals, Inc. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007, Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005, Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky.

Donald R. Joseph

Mr. Joseph currently serves as Chief Legal Officer and Board Secretary of Acer Therapeutics Inc., a publicly held biopharmaceutical company, and has served as an adviser and consultant to biopharmaceutical and global health organizations. He has over twenty years of biopharmaceutical industry experience, including senior management positions in global health non-profit organizations. Mr. Joseph served as the Chief Legal Officer and Board Secretary of Humanigen, formerly known as KaloBios Pharmaceuticals, Inc., a publicly listed company, from June 2013 to November 2015. Prior to KaloBios, he was Chief Executive Officer of BIO Ventures for Global Health, or BVGH, from February to November 2012 and Chief Operating Officer from April 2010 to January 2012. He is a former Chairman and Secretary and director of BVGH. He previously served as general counsel, corporate secretary, and in other senior management roles at publicly held biopharmaceutical companies, including Abgenix and Renovis. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world’s largest law firms. He received his J.D. degree from the University of Texas School of Law, with honors.

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Donald R. Joseph

Mr. Joseph currently serves as Chief Legal Officer and Board Secretary of Acer Therapeutics Inc., a publicly held biopharmaceutical company, and has served as an adviser and consultant to biopharmaceutical and global health organizations. He has over twenty years of biopharmaceutical industry experience, including senior management positions in global health non-profit organizations. Mr. Joseph served as the Chief Legal Officer and Board Secretary of Humanigen, formerly known as KaloBios Pharmaceuticals, Inc., a publicly listed company, from June 2013 to November 2015. Prior to KaloBios, he was Chief Executive Officer of BIO Ventures for Global Health, or BVGH, from February to November 2012 and Chief Operating Officer from April 2010 to January 2012. He is a former Chairman and Secretary and director of BVGH. He previously served as general counsel, corporate secretary, and in other senior management roles at publicly held biopharmaceutical companies, including Abgenix and Renovis. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world’s largest law firms. He received his J.D. degree from the University of Texas School of Law, with honors.

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Martin Mattingly, Pharm.D.

Dr. Mattingly served as a director of Achieve since June 2010. Since December 2014 he has served as a director of TRACON Pharmaceuticals, Inc. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007, Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005, Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky.

Jay M. Moyes

Mr. Moyes currently serves as Chief Financial Officer of Sera Prognostics, Inc., a public commercial stage biotechnology company focused on improving maternal and neonatal health through innovative biomarker approaches, and currently serves on the board of directors of BioCardia, Inc., and Puma Biotechnology, Inc. He previously served on the boards of Predictive Technology Group, Osiris Therapeutics, Inc., Integrated Diagnostics and as Chief Financial Officer and Director of Amedica Corporation (now SINTX Technologies). Mr. Moyes also served as Chief Financial Officer of CareDx, a publicly traded cardiovascular diagnostics company. Prior to that, he served as Chief Financial Officer of Myriad Genetics, Inc., a publicly held molecular diagnostics company. Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc. from 1991 until 1993, a privately held animal genetics company. Mr. Moyes held various positions with the accounting firm of KPMG from 1979 to 1991. He also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 to 2006. Mr. Moyes holds a Masters of Business Administration from the University of Utah, a Bachelor of Arts in economics from Weber State University, and was formerly a Certified Public Accountant.